Lab work moves more quickly to clinical setting
from MedPage Today
A second investigational drug in the isocitrate dehydrogenase (IDH) inhibitor class has demonstrated activity in acute myeloid leukemia (AML), a small clinical study showed. Seven of 14 patients with relapsed or refractory AML had objective responses to treatment with AG-120, an orally available inhibitor of IDH1. The clinical activity included four complete responses.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063